Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of PA1010 in HBV Patients

NCT05019040 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic HBV Infection

Interventions

DRUG: PA1010

Sponsor

Zhejiang Palo Alto Pharmaceuticals, Inc.